India, May 28 -- InflaRx N.V. (IFRX) has decided to halt the development of Vilobelimab for the treatment of pyoderma gangrenosum following the results of an interim analysis from its phase III clinical trial.
The Independent Data Monitoring Committee (IDMC), which conducted an unblinded review of the trial data, recommended stopping the study due to a lack of efficacy.
Pyoderma gangrenosum is a rare condition that causes large, painful sores on the skin, particularly on the legs. There are no approved drugs for this disease in the U.S or Europe.
Vilobelimab was granted marketing authorization under exceptional circumstances by the European Commission for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome earlier thi...